IPT therapy
 

My issue is uterine cancer discovered during a d&c. I am concerned about CTCs (circulating tumor cells) resulting from the historectomy so I am considering starting with chemotherapy first.
After reading Wiki about insulin potentiated therapy (IPT) and Life Extension (lef.org) and Susanne Somers book "Knockout Interviews with Doctors Who Are Curing Cancer" I wonder if anyone in this group has experience with this therapy. I am 66, eat a strict no-sugar no-carbs diet, use a modified Gerson program and have been for years.
They say I am stage 2 but they don't really know.

Re: IPT therapy
 

Hi -
This is a breast cancer board, and we don't have the same issue, so are not really the people to ask this question.

There must be a support site for Uterine Cancer where you can post your question for some better replies.

Re: IPT therapy
 

I was afraid that was true about the venue. I have looked for sites on uterine cancer without success so far.

I might say, however, that IPT is not just for uterine cancer, it is for all cancers of any kind.

You should check out LEF follow this link: http://www.lef.org/magazine/mag2002/...ated%20therapy

and the Wiki: http://en.wikipedia.org/wiki/Insulin...iation_therapy for more information

Re: IPT therapy
 

Hi Rosemary,

Hystersisters http://www.hystersisters.com/vb2/ has a forum for uterine cancer patients.

You might be able to find more information by searching 'endometrial cancer' such as this one: http://www.eyesontheprize.org/

Having surgery first runs the risks of 'stirring up' the cancer due to angiogenesis. Having chemo first also has the advantage of knowing whether or not certain chemo combo is effective. I think the decision needs to be made between you and your doctors. I'd strongly urge you to seek a 2nd opinon (from doctors of reputable institutions - not from patients like us.)

Below is an abstract located from PubMed about Sarcoma- not sure if it applies to uterine sarcomas:

Clin Cancer Res. 2010 Jan 15;16(2):530-40. Epub 2010 Jan 12.
NVP-BEZ235 as a new therapeutic option for sarcomas.

Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, GarcÃ*a-EcheverrÃ*a C, Mercuri M, Picci P, Scotlandi K.
Source

Laboratorio di Ricerca Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy.

Abstract

PURPOSE:

To evaluate the in vitro and in vivo effects of NVP-BEZ235, a dual pan-phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor in the three most common musculoskeletal tumors (osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma).
EXPERIMENTAL DESIGN:

Antiproliferative activity as well as the effects on migration and metastasis were evaluated in a panel of osteosarcoma, Ewing's sarcoma, as well as rhabdomyosarcoma cell lines. Moreover, simultaneous and sequential treatments were done in association with two of the most important conventional drugs in the treatment of sarcoma, doxorubicin and vincristine.
RESULTS:

NVPBEZ235 effectively blocked the pathway in in vitro and in vivo settings. Under the experimental conditions tested, the compound induced disease stasis, by arresting cells in G(1) phase of cell cycle, without remarkable effects on apoptosis. As a consequence, to obtain the maximum exploitation of its therapeutic potential, NVP-BEZ235 has been evaluated in combination with conventional cytotoxic agents, thus showing promising efficacy with either doxorubicin and vincristine. Inhibition of the phosphoinositide 3-kinase/mammalian target of rapamycin pathway increased activation of extracellular signal-regulated kinase 1/2, likely due to the presence of autocrine circuits shifting growth factor signaling toward the mitogen-activated protein kinase pathway. This supports the combined use of NVP-BEZ235 with other small signaling inhibitors. Here, we showed synergistic effects when the compound was associated with a anti-insulin-like growth factor-I receptor tyrosine kinase inhibitor. NVP-BEZ235 also inhibited cell migration and metastasis. Combination with vincristine further potentiated the antimetastatic effects.
CONCLUSIONS:

NVP-BEZ235 displays the features to be considered for sarcoma therapy to potentiate the activity of other anticancer agents. The drug is currently undergoing phase I/II clinical trials in advanced cancer patients.

Re: IPT therapy
 

And don't forget to check out the American Cancer Society website:

http://www.cancer.org/cancer/uterine...erine%20cancer

Re: IPT therapy
 

Here's a newer article on endometrial cancer:

Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97.
Endometrial cancer.

Sorosky JI.
Source

From the Department of Obstetrics and Gynecology, Hartford Hospital and the Hospital of Central Connecticut, The University of Connecticut, Hartford, Connecticut.

Abstract


The epidemiology, prevention, diagnosis, treatment, prognosis, and new International Federation of Gynecology and Obstetrics staging system of endometrial carcinoma are reviewed. Endometrial cancer has increased 21% in incidence since 2008, and the death rate has increased more than 100% over the past two decades. Precursor lesions of complex hyperplasia with atypia are associated with an endometrial carcinoma in more than 40% of cases. Endometrial cancer in white women occurs at twice the incidence as in black women, but, stage for stage, black women have a less favorable prognosis. Preoperative imaging cannot accurately assess lymph node involvement. Gross examination of depth of myometrial invasion does not have the sensitivity, specificity, positive predictive value, or negative predictive value to select women who can have lymphadenectomy safely omitted from the surgical procedure. Although surgical staging remains the most accurate method of determining the extent of disease, the therapeutic value of pelvic lymphadenectomy has not been established. The anatomical extent of lymphadenectomy and the number of lymph nodes removed to establish prognostic and therapeutic benefit are controversial. Research efforts are directed at identifying women with early stage endometrial cancer who only require total hysterectomy and bilateral salpingo-oophorectomy. Minimally invasive surgical techniques have become established as standard therapy for treating women with endometrial cancer. Women with a family history of hereditary nonpolyposis colorectal cancer are at increased risk for endometrial cancer. Conservative treatment to allow for childbearing is possible in select situations. Women with endometrial cancer should be managed by physicians experienced in the complex multimodality treatment of this disease.

Re: IPT therapy
 

Quite a few of us do have higher risks of getting uterine cancer - especially the ones with a family history of colon cancer (check out 'HNPCC' http://www.clevelandclinic.org/regis...ited/hnpcc.htm

Seems the terms of 'uterine cancer' and 'endometrial cancer' are being used interchangeably:

http://www.medicinenet.com/uterine_cancer/article.htm